Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure

被引：36
作者：
Kernt, Marcus [1 ]
Neubauer, Aljoscha S. [1 ]
Kampik, Anselm [1 ]
机构：
[1] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany
来源：
ACTA OPHTHALMOLOGICA SCANDINAVICA | 2007年 / 85卷 / 01期
关键词：
D O I：
10.1111/j.1600-0420.2006.00819.x
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：119 / 120
页数：3
相关论文
共 4 条
[1]   Preoperative infection prophylaxis with 1% polyvidon-iodine solution based on the example of conjunctival staphylococci [J].
Binder, CA ;
de Kaspar, HM ;
Klauss, V ;
Kampik, A .
OPHTHALMOLOGE, 1999, 96 (10) :663-667
[2]   Intraocular pressure after intravitreal injection of triamcinolone acetonide [J].
Jonas, JB ;
Kreissig, I ;
Degenring, R .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (01) :24-27
[3]   Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study [J].
Michels, S ;
Rosenfeld, PJ ;
Puliafito, CA ;
Marcus, EN ;
Venkatraman, AS .
OPHTHALMOLOGY, 2005, 112 (06) :1035-1047
[4]   Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration [J].
Rosenfeld, PJ ;
Moshfeghi, AA ;
Puliafito, CA .
OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :331-335
1